Experts align on several aspects of intralesional corticosteroid techniques for alopecia in a national survey.

Ahead of their graduation earlier this month, two Lake Forest High School students received national recognition for the ...

Trump's NIH cuts are gutting university labs that fuel Big Pharma's drug pipeline and pushing U.S. biotech jobs, research, ...

Pfizer's (NYSE:PFE) stock is up by a considerable 7.5% over the past month. However, we decided to pay attention to ...

Pfizer offers a high 7.4% dividend yield and trades at low valuation multiples. Click here to read more about PFE stock and ...

Big Pharma executives have not been shy about their desire for deals, but companies have been battling macro headwinds ...

Discover how U.S. biotechs can learn from China's success in affordable, high-quality drug development. Read more here.

Pfizer CEO Albert Bourla, Ph.D., has pulled back the curtain on his $1.25 billion bet on a PD-1xVEGF bispecific, revealing ...

Pfizer and other drug companies have met with the Trump administration to discuss lowering U.S. drug prices but no ...

Despite recent declines, we believe Pfizer stock is a compelling buy right now, with its current price of around $23 likely ...

ANGLE presents new data at EACR 2025 DEMONSTRATING DNA DUAL ANALYSIS FOR COMPREHENSIVE LIQUID BIOPSY PROFILING Poster highlights ANGLE's combined CTC-DNA and ctDNA analysis revealing tumour ...

U.S. drugmaker Pfizer said it would license an experimental cancer treatment from China's 3SBio Inc , paying $1.25 billion upfront and up to another $4.8 billion if developmental milestones are met.